CE NVESTOR CONFERENCE

February 12-13, 2018 New York Marriott Marquis New York, New York

bio.org/CEO • #BIOCEO18 CEO INVESTOR CONFERENCE

ow in its 20th year, WHY ATTEND? Nthe BIO CEO & Investor Conference is 88 EXPERIENCE the largest, unbiased forum where institutional investors, industry analysts, and senior biotechnology executives one of the largest investor shape the future investment landscape of the industry. conferences focused on established and emerging 88 EVALUATE fresh investment opportunities including compatible, complementary and competitive companies. publicly traded and select private biotech 88 LEARN about the hottest clinical developments and industry companies. catalysts by attending the conference’s therapeutic workshops and business roundtables.

88 ATTEND fireside chats with leading executives who will share their recent company successes and general industry perspectives.

88 GAIN ACCESS to BIO’s One-on-One Partnering system for scouting potential investments and deal partners, optimizing your time at the event.

88 HEAR presentations from more than 175 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.

88 GET THE PULSE of the current and proposed investment trends in biotechnology.

88 NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions.

FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK 288 2 2018 FIRESIDE CHAT SPEAKERS

ireside Chats feature Fcandid discussions between biopharma executives, Wall Street analysts, and other high- level industry experts. Deborah Dunsire, MD Lan Huang, PhD President and Chief Co-Founder, Chairman and Hear about recent Executive Officer Chief Executive Officer company successes, XTuit Pharmaceuticals BeyondSpring Pharmaceuticals what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2018.

Jeffrey D. Marrazzo Vivek Ramaswamy Co-Founder and Chief Founder and Chief Executive Officer Executive Officer Spark Therapeutics Roivant Sciences

Vicki Sato, PhD Rachel Sherman, MD, MPH Chairman Principal Deputy Denali Therapeutics Commissioner Chairman U.S. Food and Drug Vir Biotechnology Administration (FDA)

CEO INVESTOR BIO.ORG/CEO • #BIOCEO18 CONFERENCE 3

February 13 – 14, 2017 The Waldorf Astoria, New York, New York 2018 AGENDA

MONDAY � FEBRUARY 12

9:00 am – 4:15 pm Company Presentations 9:00 am – 10:15 am Therapeutic Panel Immuno-Oncology Milestones to Come: Pipelines Beyond CAR-T 1.0 10:30 am – 11:25 am Fireside Chat Jeffrey D. Marrazzo, Co-Founder and Chief Executive Officer, Spark Therapeutics 12:00 pm – 12:55 pm Business Session The Art of the Exit: Planning for Your Company’s Acquisition 1:00 pm – 1:55 pm Business Session Updating Your China Growth Strategy: Opportunities in Investor and Regulatory Dynamism 2:00 pm – 2:55 pm Fireside Chat Lan Huang, PhD, Co-Founder, Chairman and Chief Executive Officer, BeyondSpring Pharmaceuticals 3:00 pm – 3:55 pm Business Session Funding Cures: Prioritizing Policy Barriers to Amortization of Therapeutic Spending 4:00 pm – 4:55 pm Therapeutic Panel Advances in Dermatology: Recent Approvals and Later-Stage Trials 5:00 pm – 5:55 pm Business Session Market Outlook—How Durable is the IPO Resurgence and M&A Slowdown? 6:00 pm – 7:00 pm Welcome Reception

TUESDAY � FEBRUARY 13

9:00 am – 3:45 pm Company Presentations 9:00 am – 9:55 am Therapeutic Panel Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis 10:00 am – 10:55 am Fireside Chat Deborah Dunsire, MD, President and Chief Executive Officer, XTuit Pharmaceuticals 11:00 am – 11:55 am Business Session Policy Outlook—Implications of the Tax Code Changes of the Trump Administration 12:00 pm – 12:55 pm Fireside Chat Rachel Sherman, MD, MPH, Principal Deputy Commissioner, U.S. Food and Drug Administration (FDA) 1:00 pm – 1:55 pm Business Session Instilling Innovation Ambitions in your Leadership Culture 2:00 pm – 2:55 pm Fireside Chat Vivek Ramaswamy, Founder and Chief Executive Officer, Roivant Sciences 3:00 pm – 3:55 pm Therapeutic Panel Chronic Disease Innovation: PCSK9 Treatments’ Early Lessons for Other Therapies 4:00 pm – 4:55 pm Fireside Chat Vicki Sato, PhD, Chairman, Denali Therapeutics; Chairman, Vir Biotechnology 5:00 pm – 6:00 pm Closing Reception

4 FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK MONDAY � FEBRUARY 12

IMMUNO-ONCOLOGY MILESTONES TO COME: PIPELINES BEYOND CAR-T 1.0 9:00 am – 10:15 am As the recently approved, initial CAR-T therapies have shown they can produce dramatic improvements for some closely defined patient populations, the next phase of attention shifts to stretching those immuno-oncology (I-O) findings into additional targets, platforms, and indications. These new approaches include allogenic CAR-T products, T-cell regulators, oncolytic viruses, natural killer (NK) cells, and other I-O technologies. This session will discuss the dynamic opportunities in this space to fight cancer even more effectively. MODERATOR: Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence PANELISTS: Sadik Kassim, PhD, Vice President, Head of Process and Analytical Development, Mustang Bio Didier Landais, Global Head of Licensing, Servier Charles Link, MD, Co-Founder, Chairman, CEO, Chief Scientific Officer, NewLink Genetics Kimberly Noonan, PhD, Founder and Chief Scientific Officer, W i n d M I L* Kenneth Pienta, MD, Acting Chief Medical Officer, Cue Biopharma* Tito A. Serafini, PhD, President, Chief Executive Officer, and Co-Founder, Atreca, Inc.

THE ART OF THE EXIT: PLANNING FOR YOUR COMPANY’S ACQUISITION 12:00 pm – 12:55 pm There are times when a company for reasons such as clinical trial expense, achieving scale in a global sales force, or needing manufacturing capacity, recognizes that shareholder returns are best served by being acquired by a strategic buyer. Leadership teams that manage their process well can maximize the eventual benefits for their shareholders, employees, and patients of this transformation through careful partner identification, negotiations management, and integration planning. This session will feature experienced perspectives on the do’s and don’ts for CEOs considering options for proactive selling of their companies, rather than just reacting to external purchase offers. MODERATOR: Kimberly C. Petillo-Décossard, Partner, Cahill Gordon & Reindel LLP PANELISTS: Barbara Dalton, PhD, Vice President, Venture Capital, Pfizer Inc. Linda S. Grais, MD, President and Chief Executive Officer, Ocera Therapeutics, Inc.* Derek Hicks, Senior Director, Worldwide Business Development, Pfizer Inc. Annalisa Jenkins, MBBS, MRCP, former Chief Executive Officer, Dimension Therapeutics* Kazumi Shiosaki, PhD, Managing Director, MPM Capital; former Chief Executive Officer, Mitobridge* Neil Warma, Director, Orpheris; President & Chief Executive Officer, Opexa Therapeutics, Inc.

*invited

CEO INVESTOR BIO.ORG/CEO • #BIOCEO18 CONFERENCE 5

February 13 – 14, 2017 The Waldorf Astoria, New York, New York MONDAY � FEBRUARY 12, 2018 FIRESIDE 10:30 am – 11:25 am CHATS Jeffrey D. Marrazzo Co-Founder and Chief Executive Officer, Spark Therapeutics MODERATOR: Erin McCallister, Senior Editor, BioCentury 2:00 pm – 2:55 pm Lan Huang, PhD Co-Founder, Chairman and Chief Executive Officer, BeyondSpring Pharmaceuticals MODERATOR: Joseph Pantginis, PhD, Managing Director, Senior Healthcare Analyst, H. C. Wainwright and Co., LLC

UPDATING YOUR CHINA GROWTH STRATEGY: OPPORTUNITIES IN INVESTOR AND REGULATORY DYNAMISM 1:00 pm – 1:55 pm The policy shifts announced by the CFDA and Chinese investment authorities within the past two years have unlocked significant new opportunities for biopharma companies to access the patient population in China and obtain capital from new sources. Already the world’s second largest market for biopharmaceuticals, the increasing pace of drug reviews and harmonization of clinical trials expectations means companies should revisit their market launch prioritizations. This session will share advice from successful leaders in this market for partnering with Chinese biopharmas and investors. MODERATOR: Joseph Damond, Executive Vice President, International Affairs, Biotechnology Innovation Organization (BIO) PANELISTS: Michael Keyoung, MD, PhD, Managing Director and Head of North America, C-Bridge Capital Yuwen Liu, Founding Partner, BOHE Angel Fund; former Chairwoman & CEO, Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY)* Kimberly Nearing, Managing Director and Head of Life Sciences, Cedrus Investments Hummer Mars, Executive Director, China Group, Global Division, NYIC Amit D. Munshi, Director, President, and Chief Executive Officer, Arena Pharmaceuticals* Dan Zhang, MD, Chairman, Fountain Medical Development Ltd. (FMD)

FUNDING CURES: PRIORITIZING POLICY BARRIERS TO AMORTIZATION OF THERAPEUTIC SPENDING 3:00 pm – 3:55 pm The tradition of health systems paying for biopharma treatments by the dose gets strained when confronted by the latest therapeutic technologies that may offer multi-year benefits or lifetime relief from disease per a single administration of a highly customized therapy. Finding analogous methods of matching payment schedules to long-duration benefits, while covering up-front costs, shows how unprepared organizations are for the era of delivering access to gene therapies and other potential cures. This session will consider market-based options and identify relevant policy barriers to experimenting with amortization models and other techniques for funding non-traditional treatments that could greatly improve or extend patients’ lives. *invited

6 FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK PANELISTS: Ted Haack, Owner, Managing Partner, Haack & Associates* Jami Rubin, Managing Director, * Michael B. Weiss, Partner, Cahill Gordon & Reindel LLP

ADVANCES IN DERMATOLOGY: RECENT APPROVALS AND LATER-STAGE TRIALS 4:00 pm – 4:55 pm 2017 produced seven FDA approvals for new dermatology medicines, the most since 2014. Additionally, several treatments in late-stage clinical development suggest opportunities for new help for patients suffering from some chronic and acute skin ailments. This session will examine some of the exciting clinical results illuminating biological understanding of dermatological diseases and the emerging opportunities for investors in this space. MODERATOR: Umer Raffat, Senior Managing Director, ISI* PANELISTS: Alise Reicin, MD, Head of Global Clinical Development, Merck KGaA* Baldo Sforzolini, MD, PhD, MBA, Senior Vice President, Clinical Development, Allergan* Michael Sierra, PhD, Vice President, LEO Science & Tech Hub Neal Walker, MD, President and Chief Executive Officer, Aclaris* Tom Wiggans, Chairman and Chief Executive Officer, Dermira* Elias Zerhouni, Global Head of R&D, Sanofi*

MARKET OUTLOOK—HOW DURABLE IS THE IPO RESURGENCE AND M&A SLOWDOWN? 5:00 pm – 5:55 pm With more than 30 biotech IPOs in 2017 but M&A deal activity running at lower than average levels, the tension for CEOs is delivering a confident story of how to achieve profitable growth for investors while drug launches receive more scrutiny than ever. As large biopharmas prune their portfolios and consider their repatriation options, the expectations run high for an uptick in M&A in 2018. This session will include experienced deal makers and investors sharing their perspectives on where they see the promise of intensifying activity within the industry this year. MODERATOR: Stephen B. Thau, Partner, Morrison & Foerster LLP PANELISTS: James Cappuccio, Managing Director, H.C. Wainwright and Co., LLC Chris Garabedian, Chairman and CEO, Xontogeny Stefan D. Loren, PhD, Managing Director, Healthcare Investment Banking, Oppenheimer & Co. Michael Meyers, Interim Chief Executive Officer, Tivorsan Pharmaceuticals, Inc. Matthew Roden, PhD, Head of Strategic Corporate Development and Global BD Assessment, Bristol-Myers Squibb Sapna Srivastava, PhD, Chief Financial Officer and Chief Strategy Officer, Abide Therapeutics

*invited

CEO INVESTOR BIO.ORG/CEO • #BIOCEO18 CONFERENCE 7

February 13 – 14, 2017 The Waldorf Astoria, New York, New York TUESDAY � FEBRUARY 13

NEUROSCIENCE OF ADDICTION: LEVERS TO ATTACK THE OPIOID ABUSE CRISIS 9:00 am – 9:55 am With official recognition of the magnitude of the opioid abuse crisis, government institutions and investors are showing increased willingness to support novel approaches to attacking this health challenge. This session will explore the most promising avenues in the neuroscience of addiction and alternatives to opioid-based pain management, as well as identify the most pressing bottlenecks in our understanding of the brain’s addiction to painkillers. PANELISTS: Roger Crystal, MD, Chief Executive Officer, Opiant Robert Hadie, President and Chief Executive Officer, Egalet Corporation Lucy Lu, MD, President and CEO, Avenue Therapeutics Corey McCann, MD, PhD, Founder and Chief Executive Officer, Pear Therapeutics Peter Strumpf, President and Chief Executive Officer, Amygdala Neurosciences Inc.*

POLICY OUTLOOK—IMPLICATIONS OF THE TAX CODE CHANGES OF THE TRUMP ADMINISTRATION 11:00 am – 11:55 am As the U.S. tax code experiences its greatest changes in decades, the financial assumptions underlying investors’ valuations will shift significantly, creating some new advantages and disadvantages within the biopharma community. This session will explain in depth the implications for pre-market and for commercial biopharma companies of changes to R&D credits, orphan drug credits, repatriation conditions, and other key dimensions of the tax rules for 2018, plus where policy adjustments might be worth recommending. MODERATOR: Andrew J. Silverman, Government Analyst–Tax, Bloomberg Intelligence PANELISTS: Mitchell Cohen, Global Tax Leader Life Sciences, EY* Michael J. Graetz, Columbia Alumni Professor of Tax Law, Columbia University* Robert Masella, Partner, Shearman & Sterling* Jacqueline Perrotti, Executive Director, Tax, Allergan*

INSTILLING INNOVATION AMBITIONS IN YOUR LEADERSHIP CULTURE 1:00 pm – 1:55 pm As the scientific challenges of developing new and superior treatments increase in difficulty, corporate management’s ability to maximize the capacity of their teams to innovate becomes ever more urgent. Recent research in cognitive science and comparative stock investment results suggest clear performance advantages that more highly diversified teams and boards can deliver. Traditional recruitment processes for corporate executive teams often fail to reflect the employee bases they lead or patient populations they serve. This session will focus on practical approaches and successful examples to diversify leadership recruitment efforts, create inclusive cultures for development/retention, and better align organizations with the full measure of talented people available. MODERATOR: James Sapirstein, RPh, Chief Executive Officer, ContraVir PANELISTS: Karen Anderson, Senior Vice President, Chief Human Resources Officer, Alnylam Pharmaceuticals Wanda Bryant Hope, Chief Diversity & Inclusion Officer, Johnson & Johnson Sabrina Martucci Johnson, Chief Executive Officer, Daré Bioscience Inc.* Karen Ling, Executive Vice President, Chief Human Resources Officer, Allergan* *invited

8 FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK CHRONIC DISEASE INNOVATION: PCSK9 TREATMENTS’ EARLY LESSONS FOR OTHER THERAPIES 3:00 pm – 3:55 pm While a majority of venture funding goes into development of oncology and rare disease treatments, the broader population with chronic diseases can also look forward to innovations from established biopharmas as well as smaller companies with promising new approaches to compete with existing care options. The slower-than-projected growth of the PCSK9 segment, despite clear clinical advantages, suggests that commercialization within the chronic disease space presents particular recent challenges that companies should be prepared to overcome once their medicines receive approvals and roll-out begins. This session will highlight some exciting late-stage pipelines and review the structural challenges of convincing providers, payers, and patients of the value of a new medicine for treating a chronic disease which has existing therapeutic alternatives. MODERATOR: Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research PANELISTS: Paul A. Friedman, MD, Chairman and Chief Executive Officer, Madrigal Pharmaceuticals* Carol Gallagher, PharmD, Partner, New Enterprise Associates* Nouhad Husseini, Vice President, Head of Business Development, Regeneron Pharmaceuticals, Inc.* Jim Tobin, PhD, Vice President, Scientific Innovation, Cardiovascular & Metabolic, Johnson & Johnson Innovation

TUESDAY � FEBRUARY 13, 2018 FIRESIDE 10:00 am – 10:55 am CHATS Deborah Dunsire, MD President and Chief Executive Officer, XTuit Pharmaceuticals MODERATOR: Yasmeen Rahimi, PhD, Director, Research Analyst, ROTH Capital Partners 12:00 pm – 12:55 pm Rachael Sherman, MD, MPH Principal Deputy Commissioner, U.S. Food and Drug Administration (FDA) MODERATOR: James C. Greenwood, President and Chief Executive Officer, Biotechnology Innovation Organization (BIO) 2:00 pm – 2:55 pm Vivek Ramaswamy Founder and Chief Executive Officer, Roivant Sciences 4:00 pm – 4:55 pm Vicki Sato, PhD Chairman, Denali Therapeutics; Chairman, Vir Biotechnology MODERATOR: Kate Merton, PhD, Head, JLABS @ NYC, Johnson & Johnson Innovation

Visit bio.org/ceo for latest listings. Sessions, speakers, and presentations are subject to change.

*invited

CEO INVESTOR BIO.ORG/CEO • #BIOCEO18 CONFERENCE 9

February 13 – 14, 2017 The Waldorf Astoria, New York, New York 2018 PRESENTING COMPANIES he 2018 BIO CEO & Investor Conference will better accommodate the growing diversity of Tinvestors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, this meeting will once again feature a unique track of more than 30 high-caliber and established private company presentations. This year, BIO has introduced a new track of “Emerging Innovators” comprised of pre-Series A, but post-startup companies. See bio.org/ceo for a downloadable spreadsheet of presenting companies’ info. Cardiology Cesca Therapeutics, Inc. (NASDAQ:KOOL) Gritstone Oncology, Inc. Aralez Pharmaceuticals (NASDAQ:ARLZ) Editas Medicine, Inc. (NASDAQ:EDIT) H3 Biomedicine Berlin Cures Humanigen, Inc. (OTCQB: HGEN) Humanetics Corporation Cardiol Therapeutics Inc MangoGen Pharma Immunicum AB (Nasdaq Stockholm:IMMU.ST) Espero BioPharma, Inc. Orig3n, Inc. Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) Resverlogix Corp. (TSX:RVX) Sigilon Therapeutics Inc Inovio Pharmaceuticals (NASDAQ:INO) SQZ Biotechnologies Intensity Therapeutics, Inc. CNS/Neurological Vericel Corporation (NASDAQ:VCEL) InteRNA Technologies B.V. Abide Therapeutics Lantern Pharma Inc Amygdala Neurosciences, Inc. Immunology Leap Therapeutics Inc. (NASDAQ:LPTX) Anavex Life Sciences Corp. (NASDAQ:AVXL) CytoDyn, Inc. (OTC Markets:CYDY) Lexi Pharma Inc. Aralez Pharmaceuticals (NASDAQ:ARLZ) Gradalis, Inc. MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) Assuage Pharmaceuticals, Inc. Heat Biologics (NASDAQ:HTBX) MaxCyte, Inc. (AIM, LSE:MXCT; MXCR) Aucta Pharmaceuticals Inc. Hemispherx Biopharma, Inc. (NYSE:HEB) NanOlogy LLC Axsome Therapeutics (NASDAQ:AXSM) Immunovaccine Inc (TSX, OTCQX:IMV, IMMVF) Opsona Therapeutics Limited Bioasis Technologies Inc. (TSX.V / OTCQB:BTI / BIOAF) ImmusanT, Inc. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Berlin Cures NewLink Genetics (NASDAQ:NLNK) Race Oncology Ltd (ASX:RAC) Cardiol Therapeutics Inc Rain Therapeutics Inc. Corium International, Inc. (NASDAQ:CORI) Immuno-oncology Espero BioPharma, Inc. Immunomic Therapeutics, Inc. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Flex Pharma (NASDAQ:FLKS) Sierra Oncology (NASDAQ:SRRA) Genervon Biopharmaceuticals, LLC Infectious Diseases TapImmune Inc (NASDAQ:TPIV) Aridis Pharmaceuticals, Inc. Tarveda Therapeutics, Inc. Neuraltus Pharmaceuticals, Inc. Armis Biopharma, Inc. NeuroActiva, Inc. Vascular Biogenics Ltd (NASDAQ:VBLT) ContraVir Pharmaceuticals (NASDAQ:CTRV) Vidac Pharma NeuroRx, Inc. Lakewood-Amedex, Inc. Neurotrope (NASDAQ:NTRP) Synthetic Biologics, Inc. (NYSE American:SYN) Ophthamology Newron Pharmaceuticals SpA (SIX:NWRN) TAXIS Pharmaceuticals Inc. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Oryzon Genomics SA (BOLSA:ORY) Vical Incorporated (NASDAQ:VICL) Graybug Vision, Inc PAION AG (Xetra, Frankfurt:PA8) Nemus Bioscience, Inc. (OTCQB:NMUS) Probiodrug AG (Euronext Amsterdam:PBD) Inflammation Ocugen, Inc. Resverlogix Corp. (TSX:RVX) Immune Pharmaceuticals Inc. (NASDAQ:IMNP) pSivida Corp (NASDAQ:PSDV) Serina Therapeutics, Inc. Morphic Therapeutic Inc. TAHO Pharmaceuticals Ltd. (TPEX:tw.6467) Orphan/Rare Disease Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Medical Devices Avidity Biosciences LLC Bellerophon Therapeutics (NASDAQ:BLPH) Catalyst Biosciences (NASDAQ:CBIO) Contract Research Organization CytoSorbents Corporation (NASDAQ:CTSO) Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Brillance Femeda Ltd Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR) gel-e, Inc. Dermatology Muscular Dystrophy Association (MDA) Microdermics Inc. Palladio Biosciences, Inc. Exicure Inc. (OTCQB:XCUR) Sanuwave Health, Inc. (OTCQB:SNWV) Fibrocell Science, Inc. (NASDAQ:FCSC) Prometic Life Sciences Inc. Moberg Pharma AB (Nasdaq Stockholm:MOB.ST) Metacbolic Diseases (Toronto:TSX: PLI, OTCQX : PFSCF) Adocia (Euronext Paris: ADOC) Summit Therapeutics plc (NASDAQ:SMMT) Diagnostics Gila Therapeutics, Inc. Biocept, Inc. (NASDAQ:BIOC) Other Orexigen Therapeutics, Inc. (NASDAQ:OREX) 22nd Century Group, Inc. (NYSE:XXII) Chembio Diagnostics, Inc. (NASDAQ:CEMI) Viking Therapeutics, Inc. (NASDAQ:VKTX) Curetis N.V. (Euronext Amsterdam & Euronext Brus- Akebia Therapeutics, Inc. (NASDAQ:AKBA) sels:CURE) Multiline Global Biopharma Apricus Biosciences, Inc. (NASDAQ:APRI) Interpace Diagnostics (NASDAQ:IDXG) Dyadic International, Inc. (OTCQX:DYAI) Boston Pharmaceuticals Intuitive Biosciences, Inc. Cerecor Inc (NASDAQ:CERC) Invitae Corporation (NYSE:NVTA) Multiple Therapeutics Oramed pharmaceuticals (NASDAQ:ORMP) Mikro Biyosistemler Elektronik Sanayi ve Ticaret AŞ Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Platform for Therapeutics Navidea Biopharmaceuticals (NYSE:NAVB) Can-Fite BioPharma Ltd. (NYSE:CANF) Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) BioTime (NYSE:BTX) OncoCyte Corporation (NYSE American:OCX) Precision NanoSystems Valdia Health Galectin Therapeutics, Inc. (NASDAQ:GALT) Palatin Technologies, Inc. (NYSE:MKT:PTN) RXi Pharmaceuticals Corporation (NASDAQ:RXII) Digital Health Regenerative Medicine Pear Therapeutics, Inc. Non-Profit/Patient Advocacy Group Regenerative Medical Services Ltd. TraceLink Association for Women in Science (AWIS) Reproductive/Sexual Health Food & Agriculture Oncology Daré Bioscience, Inc. (NASDAQ:DARE) Recombinetics Inc. Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) Apexian Pharmaceuticals S1 Biopharma, Inc. Gastrointestinal Aravive Biologics Respiratory AzurRx BioPharma, Inc. (NASDAQ:AZRX) BioLineRx Ltd. (NASDAQ:BLRX) Insmed Incorporated (NASDAQ:INSM) Conatus Pharmaceuticals Inc. (NASDAQ GM:CNAT) Bio-Path Holdings, Inc. (NASDAQ:BPTH) Lung Therapeutics, Inc. Enterome SA Cellectar Biosciences (NASDAQ:CLRB) Novoclem Therapeutics Landos Biopharma CEL-SCI Corporation (NYSE American:CVM) Savara, Inc. (NASDAQ:SVRA) Leading BioSciences Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Spyryx Biosciences, Inc. OrphoMed, Inc. Cue Biopharma (NASDAQ:CUE) RedHill Biopharma Ltd. (NASDAQ/TASE:RDHL) Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Tools/Drug Development Support Tech CytRx Corporation (NASDAQ:CYTR) Scientist.com Gene/Cell Therapy Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Soplix BioLife Solutions, Inc. (NASDAQ:BLFS) Erytech Pharma (NASDAQ:ERYP) WuXi NextCODE Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Forty Seven Inc. Caladrius Biosciences, Inc. (NASDAQ:CLBS)

10 FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK 2018 PARTICIPATING INVESTORS 11.2 CAPITAL Excelyrate Capital A C Binder Corp Faridan Abbvie Ventures FC Capital Management Aceras Life Sciences Federated Kaufmann Fund Aceras Partners Ferghana Partners Acuris Partners Fineman Financial Adamas Healthcare Fund First Island Capital of investors who Aegis Capital Corp First Seafront Fund 100% AFUND First Seafront Fund Management attended in 2017 reported Agent Capital Flagship Pioneering BIO CEO Agilent Technologies Fortress Biotech Aisling Capital First Republic Investment Management that they found companies worth Aleph Capital Gagnon Securities Alignment Ventures, LLC GCF Family Office their consideration for investment. AllianceBernstein GE Ventures Allied Minds GHS Investments, LLC Ally Bridge Group GMP Securities Altaris Capital Partners GMX Capital Partners Altitude Life Science Ventures Golden Seeds MP Healthcare Venture Management Sio Capital Amzak Health Good Health Capital MSF Capital Advisors Sio Capital Management AngelMD Grant Engine Murray Capital Group Slater Technology Fund Anson Funds Greensky Capital MV Corp Services SmithOnStocks Apple Tree Partners Grey Sky Venture Partners MVM Partners Snyder Capital Management ARCH Venture Partners Griffin Securities MVP Capital Partners Sorrento Therapeutics Archer Avenue Partners Guggenheim Partners New Enterprise Associates Special Situations Funds Arcus Ventures Guggenheim Securities New Harbor Venture Partners SPRIM Aristar Capital H.C. Wainwright & Co. New Jersey Division of Investment Sprim Ventures Arjava Capital Group Hayfin Capital Management New Science Global Healthcare Fund Square 1 Arix Bioscience HCWCO New Science Ventures Stadnyk and Partners Arowgrass Health Passion Fund New York Ventures Stanphyl Capital Management Asahi Kasei America Helix Management, Inc Nexus Life Science Partners Financial Ashford Capital Management Hercules Capital NF Trinity Capital Surveyor Capital Aspire Capital Partners, LLC Horizons Ventures Noble Life Science Partners Sutton Place Management ATEL Ventures Horizons Ventures Ltd Novatio Ventures SVB ATEM Capital Hudson Bay NSIP LLC Symphonia Partners Athena Bio Ventures Humanwell Healthcare Group NY Ventures Symphony Capital LLC Atheneos Capital Illumina Ventures NYIC Syzygy Therapeutics Athyrium Capital Management Innoviva, Inc. NYS Innovation VC Fund TaiAn Technologies AuGC BioFund LP inThought Research Oberland Capital Talfinium Investments, Inc. Aurora Asset Research J.P. Morgan Omega Funds Tanaka Capital Management B. Riley FBR, Inc. Janney Montgomery Scott Opti Capital Management Tang Capital Management, LLC Bank of America Lynch JDRF T1D Fund OrbiMed Advisors TAP Advisors Bawcap Jefferies LLC Orchard View Capital Advisors Lp The Carlyle Group Bentley Associates JGB Capital Otsuka America Pharmaceutical The Leukemia & Lymphoma Society BergmorCapital Jina Ventures Otsuka Pharmaceutical Development Tosoh USA, Inc. Bigger Capital Fund, LP JMP Securities LLC & Commercialization Tralucent Asset Management BioAdvance Johnson & Johnson Innovation - JJDC Oxford Finance Tryphon Capital Biondo Investment Advisors Johnston Associates Inc. Pappas Capital Turret Capital Management Biosense Global LLC Kairos Ventures Pappas Ventures Two Sigma Ventures Biosphere Capital Ventures Kalka Fund Park Ave Capital Management UNUM Capital Biotech Alliances International Karthala Capital Management (KCM) International Valquest Capital Management Biotechnology Innovation Organization Katalyst Securities Paulson Investment Varana Capital, LLC Black Diamond Advisors, LLC Katalyst Securities LLC Peak One Opportunity Fund, LP Vector Capital BMO Capital Katz Associates Petrichor Healthcare Capital venBio Bohe Angel Fund KESA Partners Inc. Management Versant Ventures Bojian Capital Kingdon Capital Pharmakon Advisors Virtus Inspire Ventures Brace Pharma Capital Knoll Capital Management PHX Financial Vista Capital Advisors Bridgebio Pharma Llc Knott Partners, LP Piper Jaffray & Co. Vivo Capital Brock Capital L2 Capital Pivotal BioVenture Partners W Global Capital Ltd. Brookline Capital Markets L2 Capital, LLC Portola Capital Partners Wallachbeth Capital C-Bridge Capital Ladenburg Thalmann Prevail Partners, LLC WBB Asset Management CANA Partners LaidLaw and Company Princeton BioPharma Capital Partners WBB Securities Cato BioVentures Asset Management Promethean Capital Group, LLC Weigao Group CEC Capital Lexington Capital Management QILU Pharmaceutical Wellington Shields & Co. Cedrus Investments LifeScience Equity Partners, LLC Questrion WestPark Capital Chardan LifeTech Capital RBC Capital Markets Windrose Health Investors Chardan Capital Markets, LLC Lincoln Park Capital Relentless Pursuit Partners Wolf Capital Management Chia Tai Tianqing Pharmaceutical Group Little Gem Life Science Partners Remiges Ventures Wolfswood Partners Church Pension Fund Livingston LLC RHK Capital LLC Yale University CL Investment Group Locust Walk Capital Rho Ventures Xeraya Capital Life Venture Crescent Capital Ventures LLC Longitude Capital Robert W. & Co., Inc. Zenith Capital Cross Current Research LLC LSWorks LLC Rockport Venture Fund CSC Leasing Lumira Capital Rolin Capital CS McKee LYFE Capital Roosevelt Investments CTI Life Sciences Madison Square Capital LLC Roth Capital Dabar Investment Associatees Marathon Asset Management Roth Capital Partners Dec Family Ventures, LLC Mass Innovation Labs RTP Capital Deca Ventures, LLC Maxim Group S&A Investments Deerfield Management Maytech Global Investments Sabby Management, LLC INVESTOR Discover Fund MAZ Capital Advisors Sagestone Capital / Elmwood Capital Discover Fund Management LLLP Medex Santen Ventures REGISTRATION DoubleRock LLC Medex Capital Satter Management Douglas C. Lane & Associates Medpro Investors LLC SBP Management UP MORE THAN DROIA nv Mentor Capital Partners Ltd Schonfeld Strategic Advisers Dynamk Capital Meyers Investments Family Sea Otter Global Ventures Easton Capital Mid Atlantic Bio Angels (MABA) Seaport Global Securities Efrat Investments Militia Hill Ventures Second Line Capital Mgmt EGB Ventures Serrado Capital Ensign Peak Advisors Mizuho Securities Seventure 35% Enso Ventures Shattemac Capital Management OVER 2017. Esousa Holdings LLC Morgens, Waterfall, Vintiadis & Co. Shaw Strategic Capital Evepine Capital Mossrock Capital SilverArc Capital Excelyrate Mossrock Capital, LLC Silver Arrow Partners

CEO INVESTOR BIO.ORG/CEO • #BIOCEO18 CONFERENCE 11

February 13 – 14, 2017 The Waldorf Astoria, New York, New York BIO ONE-ON-ONE PARTNERING MEETINGS SCHEDULED MEETINGS Using the system, UP 21% BIO’s One-on-One companies SINCE 2015 Partnering™ system is the interactive are able to: platform that allows 88 Pre-schedule 30-minute private 1x1 meetings you to increase your 88 Source potential collaborations and funding productivity, discover opportunities with an international audience new investment and licensing opportunities, 88 Communicate directly with prospective and expand your business investors and C-level executives in biotech potential worldwide. and pharma 88 Search company and investor profiles for potential business partnerships

AUDIENCE DEMOGRAPHICS Attendees: 1,400+ Countries Represented: Job Profile: 28 BIO One-on-One 76% Partnering Meetings: 76% of attendees 2,600+ 76% are VP or C-Level Registered Investors: 650 9% 15% 62% 14% Company Presentations: 190 Other Director C-level VP Expert Speakers: 58

Companies Profile: Breakdown by Therapeutic Focus:

Metabolic Diseases: 4% Cardiovascular: 4% 58% of all companies Gastrointestinal: 4% 58% attending are biopharma Infectious Diseases: 5% Oncology: 31%

Gene/Cell Therapy: 5%

Breakdown by Market Cap: Orphan/Rare Diseases: 6% $250M-500M: 4% >$500M: 13% Diagnostics: 7% Other: 26%

$50M-100M: 16% < $50M: 42% CNS/Neurological: 9%

$100M-250M: 25%

12 FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK SPONSORS DOUBLE HELIX SPONSORS

SUPPORTING BANK SPONSORS

CONFERENCE SPONSORS

CO-HOSTS

MEDIA PARTNERS

CEO INVESTOR BIO.ORG/CEO • #BIOCEO18 CONFERENCE 13

February 13 – 14, 2017 The Waldorf Astoria, New York, New York ADVISORY COMMITTEE February 12-13, 2018 • New York Marriott Marquis

John Chambers Eric Cheng Manon Cox, PhD Carol Gallagher, Linda S. Grais, MD President and Head of Managing Director, Transition Task Force PharmD President and Chief Investment Banking Head of Healthcare Leader (former President Partner Executive Officer H.C. Wainwright & Co. Investment Banking and CEO) New Enterprise Ocera Therapeutics, Inc. ROTH Capital Partners Protein Sciences Associates Corporation (acq. Sanofi Pasteur 2017)

Nouhad Husseini Jonathan Leff Michael Margolis, RPh Timothy P. Jason Park, PhD Vice President, Head of Partner, Deerfield Co-Head of Healthcare O’Connor, PhD Principal Business Development Management; Chairman Investment Banking Executive Vice President Flagship Pioneering Regeneron Deerfield Institute Oppenheimer & Co. The Rockefeller University Pharmaceuticals, Inc.

Susan Peschin, MHS Dennis J. Purcell Stephen M. Ritoch Carlo Rizzuto, PhD, Matthew President and Chief Founder and Senior Chairman and CEO Partner Roden, PhD Executive Officer Advisor Blaise Group Versant Ventures Head of Strategic Alliance for Aging Aisling Capital International Corporate Development Research and Global BD Assessment Bristol-Myers Squibb

Sapna Srivastava, PhD Nassim Usman, PhD Chief Financial Officer President and Chief and Chief Strategy Officer Executive Officer Abide Therapeutics Catalyst Biosciences

14 FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK REGISTRATION AND HOUSING INFORMATION

offers a number of ways to conference attendees to save money on BIOtheir registration fees. Discounted rates apply to the following: 88 Companies bringing more than three employees. 88 Academic, government and non-profit institutions. 88 Service providers suppliers. Qualified institutional and venture investors are eligible for complimentary registration.

CONTACT BIO REGISTRATION EMAIL: [email protected] TEL: +1.202.962.6655 New York Marriott Marquis THIS 1535 Broadway, New York, NY 10036 YEAR’S EVENT 212.398.1900 IS AT A Book your room today to also receive NEW VENUE! the discounted room rate. Reservation requests are based on availability, space is limited.

CEO INVESTOR BIO.ORG/CEO • #BIOCEO18 CONFERENCE 15

February 13 – 14, 2017 The Waldorf Astoria, New York, New York HOSTED BY: